ArticleJournal of Taibah University Medical Sciences2025
Exploring the absence of LMP1-XhoI deletion in nasopharyngeal carcinoma patients: A genetic perspective.
Article in Journal of Taibah University Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nasopharyngeal carcinoma (NPC) is the most common type of head and neck cancer, and its development is closely linked to Epstein-Barr virus (EBV). Notably, changes in the viral Latent Membrane Protein 1 (LMP-1) gene, such as the absence of the Xhol restriction site, contribute to its oncogenic properties. This study was to explore the connection between the XhoI site and NPC progression, with the goal of enhancing early diagnosis and treatment strategies. Methods: Formalin-fixed paraffin-embedded (FFPE) tissues from NPC patients were collected, and using restriction fragment length polymorphism (RFLP-PCR), variants of the EBV LMP-1 XhoI gene were identified, followed by amplification of the BamHI-W gene. Results: EBV DNA was detected in all NPC tissue samples via amplification of the BamHI-W region, confirming widespread EBV association in the Jordanian cohort. Wild-type (WT) XhoI variant was identified in 82.86 % of NPC cases, whereas no samples exhibited the mutant-type (MT) XhoI variant, as substantiated by Sanger Sequencing of representative cases. Statistical analysis revealed no significant correlation between the presence of WT XhoI and variables such as patient sex, age, tissue origin, NPC subtype, or disease stage. Notably, most samples from stage III/IV harbored the WT XhoI variant. Overall, BamHI-W gene detection proved to be a more consistent molecular marker than LMP-1 XhoI in this population, and no relationship was established between LMP-1 XhoI mutation and NPC development. Conclusion: These findings primarily highlight the epidemiological association between EBV and NPC in Jordanian patients, rather than demonstrating immediate clinical applicability for screening or early diagnosis. The absence of the LMP-1 XhoI deletion in this cohort underscores significant geographic and ethnic heterogeneity in the prevalence of this genetic alteration among NPC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.